# Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002)

> **NCT00670488** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 104 (actual)

## Conditions studied

- Locally Advanced Tumors
- Metastatic Solid Tumors
- Cancer
- Neoplasms

## Interventions

- **DRUG:** MK-2206

## Key facts

- **NCT ID:** NCT00670488
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04-15
- **Primary completion:** 2011-07-11
- **Final completion:** 2011-07-11
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2019-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00670488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00670488, "Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00670488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*